Maria Sklodowska-Curie National Research Institute of Oncology

What Maria Sklodowska-Curie National Research Institute of Oncology does

The Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (NIO-PIB) is Poland's largest oncology center and a leading institution in Central Europe, operating as a unified state research institute delivering comprehensive cancer care, translational research, and public health coordination. Founded in 1932 as the Radium Institute and renamed in honor of Maria Skłodowska-Curie, the institute runs four locations — two in Warsaw (ul. W. K. Roentgena 5 and ul. Wawelska 15), plus regional branches in Gliwice and Kraków — and conducts approximately 500,000 patient consultations annually at its Warsaw headquarters alone. Its clinical and research infrastructure includes the Centrum Doskonałości Onkologii Precyzyjnej (Precision Oncology Center of Excellence), Poland's first Oddział Badań Wczesnych Faz (Early-Phase Clinical Trials Unit), an institutional Biobank, and the Centrum Medycyny Cyfrowej (Digital Medicine Center), collectively supporting over 500 active clinical trials spanning early-phase to late-phase studies.

NIO-PIB's service portfolio spans the full oncology pathway: preventive screening (HPV HR testing, liquid cytology, mammography via the Centrum Profilaktyki Nowotworów), precision diagnostics, surgical and radiotherapy (including pediatric radiotherapy), chemotherapy, targeted therapies, palliative care, and survivorship follow-up, complemented by psychological, nutritional, and rehabilitation support services. The institute functions as a national coordinator of Poland's oncology strategy, managing the Krajowy Rejestr Nowotworów (National Cancer Registry), serving as the National Monitoring Center for the Krajowa Sieć Onkologiczna (National Cancer Network), and acting as Poland's reference center for rare adult cancers through the EURACAN European Reference Network. As a public sector research institute, NIO-PIB is primarily funded through the Narodowy Fundusz Zdrowia (NFZ) for clinical services, supplemented by government grants, EU research funding, clinical trial sponsorship, and a commercial subsidiary (OncoTransfer sp. z o.o.) for technology transfer. Its customers are Polish oncology patients (via the national healthcare referral system and a national helpline), pharmaceutical and biotech clinical trial sponsors, and the Polish government for policy coordination.

Name

Maria Sklodowska-Curie National Research Institute of Oncology

Legal name

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy

Website

https://pib-nio.pl

Company type

Private

Founded year

1932

Operating status

Operating

Headcount range

501–1,000 employees

Short description

NIO-PIB is Poland's largest oncology center and a state research institute, delivering comprehensive cancer care, clinical trials, and precision oncology across four locations in Warsaw, Gliwice, and Kraków. It coordinates the National Oncology Strategy, manages the National Cancer Registry, and serves as Poland's EURACAN reference center for rare cancers.

Ownership category

akta.pro rank

Product category

Cancer Treatment and Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical and Diagnostic Laboratories (6215), Diagnostic Imaging Centers (621512), General Medical and Surgical Hospitals (622110)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Oncology Specialty Pharmaceuticals (HLAIACAA), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK)

Keywords

• Oncology diagnostics
• Cancer treatment
• Clinical research
• Cancer prevention
• Precision oncology

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Public Healthcare Services (NFZ Reimbursement): As a public research institute and national oncology center, NIO-PIB is primarily funded through Poland's public healthcare financing system (Narodowy Fundusz Zdrowia, NFZ), providing reimbursed diagnostic and therapeutic services to patients under the national health insurance scheme. Revenue is derived from contracted healthcare services.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

As Poland's largest oncology center and national reference institution, NIO-PIB delivers comprehensive cancer diagnostics, treatment (including radiotherapy, chemotherapy, and surgery), and follow-up care for adult and pediatric patients across four locations. The institute conducts over 500 clinical trials and operates centers of excellence in precision oncology, early-phase clinical research, and digital medicine. It also coordinates Poland's National Oncology Strategy 2020-2030 and manages the National Cancer Registry.

Product overview

The Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie (NIO-PIB) is Poland's largest oncology center and a leading institution in Central Europe, operating as a unified healthcare and research institution. The institute provides a comprehensive portfolio of oncology services organized around four core pillars: clinical diagnostics, cancer treatment, clinical research, and cancer prevention. The institution integrates specialized departments including the Early Phase Research Unit, Clinical Trial Support Center, and Precision Oncology Center of Excellence to deliver over 500 clinical trials annually. Patient care encompasses the entire oncology pathway from preventive screenings through diagnosis, treatment, and survivorship follow-up, supported by multidisciplinary expert teams. The institute also serves as the national coordinating body for the National Oncology Strategy, managing the National Cancer Registry and developing diagnostic-therapeutic guidelines.

Differentiator

Problem solved

Functional benefit

Brands

• Centrum Profilaktyki Nowotworów (Cancer Prevention Centre): Center providing free preventive examinations including HPV HR tests, liquid cytology, and mammography.
• Centrum Doskonałości Onkologii Precyzyjnej (Centre of Excellence in Precision Oncology)
• Polish Cancer Mission Hub
• OncoTransfer sp. z o.o.

Products and services

• Cancer Treatment Comprehensive oncological treatment including radiotherapy (including pediatric), chemotherapy, surgical oncology, targeted therapies, and specialized clinics serving adult and pediatric oncology patients across Warsaw, Gliwice, and Krakow.
• Cancer Diagnostics Precision diagnostic services including laboratory testing, PET/scintigraphy, diagnostic imaging departments, and specimen collection points serving cancer patients and at-risk populations.
• Clinical Trials Services Clinical trial infrastructure supporting over 500 ongoing oncology studies, including Poland's first Early Phase Research Unit, a Clinical Trial Support Center, and the Precision Oncology Center of Excellence, available to pharmaceutical and biotech sponsors.
• Preventive Examinations Program Free preventive screening programs including HPV HR testing, liquid cytology for cervical cancer prevention, and mammography for breast cancer screening, available to the general Polish population through the Centrum Profilaktyki Nowotworów (Cancer Prevention Centre).
• Cancer Prevention Centre Primary and secondary cancer prevention programs, epidemiological surveillance, smoking cessation clinic (Poradnia Pomocy Palącym), and management of the National Cancer Registry (Krajowy Rejestr Nowotworów).
• National Oncology Strategy Coordination Coordination of the National Oncology Strategy 2020-2030 implementation, management of the National Cancer Registry, development of diagnostic-therapeutic guidelines, and operation of the National Monitoring Centre (Krajowy Ośrodek Monitorujący) for the Krajowa Sieć Onkologiczna (National Cancer Network).
• Supportive Care Services Comprehensive patient support including psychological support, rehabilitation, nutritional care, social worker services, chaplaincy (duszpasterstwo), and patient follow-up visits.

Quantifiable outcome

• ~500,000 consultations annually in Warsaw headquarters alone
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core.

• EURACAN (European Reference Network for Rare Adult Cancers)coreStrategic or Co-development PartnerNIO-PIB is a member of the EURACAN European Reference Network for rare adult cancers, serving as a national reference center for rare cancer cases. This membership enables cross-border consultation and treatment coordination for rare oncology cases within Europe.
• OECI (Organisation of European Cancer Institutes)coreStrategic or Co-development PartnerActive membership in OECI, the pan-European organization of cancer institutes, supporting collaborative research, best practice sharing, and accreditation programs across European oncology institutions.
• ESMO (European Society for Medical Oncology)coreStrategic or Co-development PartnerLong-standing collaboration with ESMO, participating in guideline development, educational programs, and international research initiatives that shape European oncology standards.
• EORTC (European Organisation for Research and Treatment of Cancer)coreStrategic or Co-development PartnerCollaborates with EORTC on clinical trial design, translational research, and multicenter oncology studies at the European level.
• ESTRO (European Society for Radiotherapy & Oncology)coreStrategic or Co-development PartnerPartnership with ESTRO supporting radiotherapy research, education, and the development of radiation oncology standards across Europe.
• ASCO (American Society of Clinical Oncology)coreStrategic or Co-development PartnerCollaboration with ASCO through conference participation, guideline development, and research contribution to global clinical oncology knowledge.
• IARC (International Agency for Research on Cancer)coreStrategic or Co-development PartnerPartnership with WHO's IARC contributing to international cancer research, epidemiology, and the development of global cancer prevention strategies.
• Polish Ministry of Health / Government of PolandcoreStrategic or Co-development PartnerNIO-PIB serves as the national coordinating institution for the National Oncology Strategy (NSO) 2020–2030, a government program coordinated through the Ministry of Health. The institute also participates in implementing the National Cancer Network (Krajowa Sieć Onkologiczna) and manages the National Cancer Registry.
• KSO – Krajowa Sieć Onkologiczna (National Cancer Network)coreStrategic or Co-development PartnerNIO-PIB serves as the Krajowy Ośrodek Monitorujący (National Monitoring Center) for the National Cancer Network, coordinating the reorganization and quality improvement of oncology care delivery across Poland.
• Polish Cancer Mission HubcoreStrategic or Co-development PartnerNIO-PIB hosts the Polish Cancer Mission Hub, part of the EU Cancer Mission network, supporting national coordination of cancer research missions, policy alignment, and international collaboration on cancer prevention and care.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• European Institute of Oncology (IEO): Italian comprehensive cancer center founded by Umberto Veronesi that integrates prevention, diagnosis, treatment, and clinical research under one institution. Comparable to NIO-PIB in combining a national reference role with precision oncology research.
• Gustave Roussy Institute: France's leading comprehensive cancer center and one of Europe's largest oncology hospitals and research institutes. Directly comparable to NIO-PIB as a national-level integrated oncology provider combining clinical care, early-phase trials, and translational research.
• Netherlands Cancer Institute (NKI): Dutch national cancer research and treatment hospital combining comprehensive oncology care with a strong research and clinical-trial infrastructure. Closely comparable to NIO-PIB in mission, scope, and scale of integrated cancer services.
• Karolinska University Hospital / Karolinska Comprehensive Cancer Center: Swedish academic comprehensive cancer center combining university hospital care, clinical trials, and translational research. Comparable to NIO-PIB in operating as an integrated national-level oncology platform within a public healthcare system.
• Institute of Cancer Research (ICR) / Royal Marsden: UK research institute and hospital partnership specializing in oncology research, early-phase trials, and treatment. Comparable to NIO-PIB in combining a national-level research mandate with precision oncology and clinical-trial leadership.

Regional players

• National Institute of Oncology Hungary (OOI): Hungary's national oncology institute providing comprehensive cancer care, research, and prevention. Directly comparable to NIO-PIB in serving as a Central European national reference center for oncology within a public healthcare system.
• Vienna General Hospital (AKH) / Comprehensive Cancer Center Vienna: Austria's leading university hospital with a dedicated comprehensive cancer center. Comparable to NIO-PIB in combining public-hospital oncology services with research infrastructure, but operates in a different CEE/Central European market.
• Masaryk Memorial Cancer Institute (MMCI): Czech Republic's largest specialized oncology hospital and research institute. Closely comparable to NIO-PIB as a Central European national cancer center operating under public healthcare reimbursement with similar scope of clinical and research services.

Broad incumbents

• German Cancer Research Center (DKFZ): Germany's national cancer research agency with strong translational research and clinical-trial infrastructure. Comparable to NIO-PIB's research pillar, including molecular profiling and biobank-driven translational programs.
• MD Anderson Cancer Center: Globally leading US oncology hospital and research center with a much larger scale than NIO-PIB. Comparable as a comprehensive cancer center combining clinical care, research, and prevention with international referral reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nio-pib

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maria Sklodowska-Curie National Research Institute of Oncology